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by Human Macrophages
BARRY R. BLOOM1 and ROBERT L. MODLIN2
1Harvard School of Public Health, Boston, MA 02115; 2David Geffen School of Medicine,
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ABSTRACT The key question our work has sought to address
has been, “What are the necessary and suﬃcient conditions
that engender protection from intracellular pathogens in the
human host?” The origins of this work derive from a
long-standing interest in the mechanisms of protection against
two such paradigmatic intracellular pathogens, Mycobacterium
tuberculosis and Mycobacterium leprae, that have brilliantly
adapted to the human host. It was obvious that these pathogens,
which cause chronic diseases and persist in macrophages,
must have acquired subtle strategies to resist host microbicidal
mechanisms, yet since the vast majority of individuals infected
with M. tuberculosis do not develop disease, there must be
some potent human antimicrobial mechanisms. What follows
is not a comprehensive review of the vast literature on the role
of human macrophages in protection against infectious disease,
but a summary of the research in our two laboratories with
collaborators that we hope has contributed to some
understanding of mechanisms of resistance and pathogenesis.
While mouse models revealed some necessary conditions for
protection, e.g., innate immunity, Th1 cells and their cytokines,
and major histocompatibility complex class I-restricted T cells,
here we emphasize multiple antimicrobial mechanisms that
exist in human macrophages that diﬀer from those of most
experimental animals. Prominent here is the vitamin
D-dependent antimicrobial pathway common to human
macrophages activated by innate and acquired immune
responses, mediated by antimicrobial peptides, e.g., cathelicidin,
through an interleukin-15- and interleukin-32-dependent
common pathway that is necessary for macrophage killing of
M. tuberculosis in vitro.
SOME NECESSARY CONDITIONS
FOR PROTECTION
While animal models of human disease have provided
great insights that would have been difﬁcult to achieve in
studies in humans, our initial experiments on protection
against Mycobacterium tuberculosis were designed to
take advantage of transgenic knockout mice. While
animal models have contributed enormously to our
understanding, it must be noted that none faithfully re-
produces the pathology or course of disease of human
tuberculosis (TB) or leprosy. With that caveat, we ex-
plored the question of immunologically necessary con-
ditions for protection of mice against M. tuberculosis
infection. We found that mice lacking the gene for
gamma interferon (IFN-γ) died from M. tuberculosis
challenge in a matter of 2 to 3 weeks after intravenous
challenge and within a month after aerosol challenge
(1). We hypothesized that the pathology observed in
the lungs would likely be mediated by local production
of tumor necrosis factor alpha (TNF-α) and were quite
surprised to learn that TNF-α-depleted mice succumbed
with precisely the same time to death as the IFN-γ
knockouts (2). Additionally, we (3) and others (4, 5)
found that mice whose major histocompatibility com-
plex (MHC) class I presentation to cytotoxic T lym-
phocytes (CTLs) was deﬁcient, e.g., β2-microglobulin
deﬁcient or TAP (transporter associated with antigen
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processing) deﬁcient, succumbed to TB infection far
earlier than control mice, but many weeks later than
the IFN-γ- and TNF-α-deﬁcient mice (1) (Fig. 1). These
results established that IFN-γ and TNF-α are necessary
for initial protection in mice, likely mediated by innate
immunity and cytokine-activated macrophages, and sug-
gested that CTLs may play a role later in infection.
MOUSE MACROPHAGE
MICROBICIDAL MECHANISMS
The experiments in vivo were followed by in vitro
experiments on mouse macrophages to learn how the
cytokines IFN-γ and TNF-α contributed to protection.
Activation by IFN-γ and TNF-α revealed that mouse
macrophages were able to kill M. tuberculosis, but the
mechanism was mediated by the action of reactive
oxygen intermediates, which were also effective against
many other pathogens (6). In 1991, Chan et al. estab-
lished that while the killing ofM. tuberculosis by mouse
macrophages was not affected by inhibitors of reactive
oxygen intermediates, the killing was dramatically re-
duced by inhibitors of nitric oxide synthase (NOS2) and
thatM. tuberculosis was directly killed by NO itself (7).
In elegant experiments, MacMicking et al. established
the importance of macrophage killing by NO in vivo by
demonstrating that NOS2 knockout mice died rapidly
from M. tuberculosis. Of interest, the time of death was
not quite as rapid as in the case of the IFN-γ knockouts
(8). These results indicated that the major mediator of
FIGURE 1 Necessary conditions for protection in mice. Depletion of IFN-γ (A), TNF-α (B),
or MHC class I (C) results in increased susceptibility and death following M. tuberculosis
challenge in C57BL/6 mice. B2M, beta-2 microglobulin; BCG, Bacillus Calmette–Guérin;
GKO, IFN-gamma gene knock out; WT, wild type. Sources: references 1–3.
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macrophage killing of M. tuberculosis in the mouse
was reactive nitrogen intermediates. Mycobacteria have
evolved multiple mechanisms to resist oxygen radicals
(6, 9) and nitrogen radicals (10–12), including scav-
enging of radicals by surface carbohydrates, and enzy-
matic mechanisms.
LEARNING FROM HUMAN LESIONS
The battle between the tubercle or leprosy bacillus and
the host macrophages is fought at the site of disease in
the tissue lesions. Establishing what is happening in the
lungs of TB patients at any stage in the disease has been
extremely difﬁcult. In contrast, leprosy is essentially a
skin disease, accessible for study by biopsy used for di-
agnosis, staging, and assessing prognosis. Consequently,
we sought to characterize the events occurring in lesions
of human leprosy. One of the fascinations of leprosy is
that it does not exist as a single clinical entity, but rather
is a spectrum. At one pole of the spectrum, tuberculoid
leprosy, there are well-organized granulomas and well-
differentiated macrophages but almost no acid-fast ba-
cilli. At the other pole, lepromatous leprosy, there are
macrophages full of acid-fast Mycobacterium leprae,
very few lymphocytes, and the granulomas are dis-
organized (Fig. 2). Most patients are classiﬁed as “bor-
derline” and show lesions with mixed characteristics.
Leprosy forms are not always static and patients can
undergo reactional states moving toward either pole.
Tuberculoid lesions have a preponderance of CD4 Th1
cells, while lepromatous lesions have few CD4 and CD8
Th2 cells (13). Analysis of gene expression in lesions
revealed that in tuberculoid lesions IFN-γ, interleukin-2
(IL-2), and lymphotoxin predominate, while in polar
lepromatous lesions IL-4, IL-5, and IL-10 predominate
(14, 15), which was the ﬁrst example of the Th1 and Th2
dichotomy, previously described in mice (16), existing in
human disease lesions.
THE INNATE AND ACQUIRED
VITAMIN D-DEPENDENT ANTIMICROBIAL
MECHANISM OF HUMAN MACROPHAGES
If, as is generally assumed, the infectious dose of M.
tuberculosis required to cause infection and disease in
humans is of the order of 1 to 400 bacilli, our ﬁrst ap-
proach was to explore the ability of cells of the innate
immune system to respond to the pathogen. This is of
particular interest in light of the ﬁnding of many in the
ﬁeld that there are people with high levels of expo-
sure to M. tuberculosis who remain healthy and fail to
convert their tuberculin skin test. That suggests that
the innate immune system may have the capability of
effectively killing the initial low level of transmitted
bacilli so rapidly that the bacilli are unable to multiply to
a level required to engage the acquired T-cell response.
In that context, it seemed important to pursue innate
mechanisms of killing of intracellular mycobacteria by
human monocytes and monocyte-derived macrophages
stimulated through the Toll-like receptors (TLRs) through
in vitro studies. Human peripheral blood precursors can
be differentiated in vitro into macrophages or dendritic
cells (DCs) when cultured in different cytokine-containing
growth media. Macrophages were derived from cultures
with macrophage colony-stimulating factor (M-CSF) or
granulocyte-macrophage CSF (GM-CSF), and DCs were
FIGURE 2 Macrophages in leprosy lesions. Cellular inﬁltrates in tuberculoid and lepro-
matous leprosy lesions. The third panel shows an acid-fast stain, indicating the abundance
of bacilli in lepromatous lesions. Courtesy of Thomas H. Rea.
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differentiated with GM-CSF + IL-4, and each possessed
characteristic surface markers. When these cells were
cultured in appropriate human sera for 4 days followed
by activation via the innate immune receptor TLR2, we
found a striking reduction in M. tuberculosis CFU by
macrophages but not by the DCs (17, 18). Surprisingly,
while the NOS2 inhibitor L-NIL was able to almost
completely block killing of M. tuberculosis by TLR2-
activated mouse macrophages, it had almost no effect
on killing by activated human macrophages (Fig. 3). This
was the ﬁrst evidence that human macrophages, at least
in vitro, kill M. tuberculosis by a mechanism different
from that of mouse macrophages.
Those ﬁndings led to experiments seeking to learn
which genes were expressed by macrophages but not
expressed by DCs following TLR2 stimulation (18).
Using two-way analysis of variance, there were three
genes predominantly expressed in the microbicidal mac-
rophages and not in DCs: S100A12; the vitamin D re-
ceptor (VDR); and Cyp27B1, the enzyme that converts
25-hydroxyvitamin D to the active 1,25-dihydroxy-
vitamin D. That, for the ﬁrst time, suggested a role for
vitamin D in the microbicidal process. When cathelicidin
and β-defensin 2 (DEFB4), known downstream products
of Cyp27B1 related to antimicrobial activity, were
screened for in macrophages activated by TLR2 ligand
alone, neither of the mRNAs for these antimicrobial
peptides was expressed. However, when the macro-
phages were stimulated by TLR2 ligand in the presence
of 25-hydroxyvitamin D, mRNAs for cathelicidin and
DEFB4 were stimulated 5- to 20-fold (19). We also
demonstrated induction of the active form of cathe-
licidin, a 37-amino-acid amphipathic α-helical antimi-
crobial peptide cleaved from a large precursor, encoded
by the CAMP gene (18). We were able to establish that
the cathelicidin peptide itself was capable of killing
M. tuberculosis in culture. Further, although it is well
known that M. tuberculosis in macrophage phagocytic
vacuoles is able to block fusion of lysosomes and is re-
fractory to many cellular proteins, including the NADP
oxidase, we were able to observe that the cathelicidin
peptide in TLR2-activated cells was colocalized with
green ﬂuorescent protein-labeled mycobacteria within
the phagocytic vacuole (18). The formal demonstration
that cathelicidin and DEFB4 were critical for killing
of M. tuberculosis in human macrophages in vitro was
the demonstration that small interfering RNA to cat-
helicidin essentially eliminated the antimicrobial activity
(20) (Fig. 4).
Multiple reports in the literature concluded that, in
contrast to murine macrophages, IFN-γ, the best-studied
T-cell mediator of macrophage activation, was not
able to activate human monocyte-derived macrophages
in vitro to kill M. tuberculosis (21–28). However, we
were able to show that the vitamin D-dependent anti-
microbial pathway, with expression of cathelicidin
and DEFB4, is induced in human macrophages by the
acquired immune response in vitro and mediated by
FIGURE 3 Inducible NOS2 (iNOS) is essential for killing of M. tuberculosis by activated
mousemacrophages in vitro but not for humanmonocyte-derivedmacrophages. L-NIL is
an inhibitor of NOS2. Source: reference 17.
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IFN-γ (Fig. 5B) (29). Thus both innate and acquired
immune-activated human macrophages, through TLR2
triggering of the MyD88 signaling pathway or through
activation by the type II IFN IFN-γ of a STAT1-mediated
pathway, were able to kill M. tuberculosis. It is perhaps
signiﬁcant that the same antimicrobial pathway is con-
served through evolution of the innate and adaptive
immune system, though induced by two different im-
mune mechanisms of activation acting through two
different signaling pathways (29).
FIGURE 5 (A) Failure of TLR2-activated human macrophages to induce cathelicidin
(Cath.) mRNA in culture with sera from African Americans can be reversed by addition
of 25-hydroxyvitamin D. (B) IFN-γ activates human macrophages to produce cathelicidin
to a comparable extent as the innate response to TLR2 agonists. Production of cathelicidin
mRNA is dependent on vitamin D and inhibited by VAZ, a VDR antagonist. Vitamin D is
essential for human macrophages activated by either TLR2 or IFN-γ to kill M. tuberculosis
in vitro. FC, fold change. Sources: references 18, 29.
FIGURE 4 TLR2-activated human monocyte-derived macrophages are able to kill
M. tuberculosis, whereas activated DCs (derived by culture of monocytes with GM-CSF
and IL-4) were unable to kill under the same conditions. **P ≤ 0.01. Source: reference 18.
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In all these experiments, inhibition of the VDR by a
chemical VDR antagonist, VAZ, blocked the induction
of cathelicidin, DEFB4, and the antimicrobial activity.
Thus the killing of M. tuberculosis in human macro-
phages in vitro was mediated by the vitamin D antimi-
crobial mechanism, not by oxygen or nitrogen radicals.
The mechanism does not appear to be important in
mouse macrophages, which have a CAMP homolog,
but one which lacks any vitamin D responsive elements
(30). This makes sense since mice are essentially noc-
turnal animals that have little exposure to sunlight. Only
some primates and humans have the vitamin D respon-
sive elements in their CAMP. The failure of previous
studies to observe killing of M. tuberculosis in human
macrophages is most likely due to the culture of the
cells either in fetal calf serum, which has negligible levels
of 25-hydroxyvitamin D, or in human sera that lacked
sufﬁcient levels. While our experiments clearly demon-
strate a novel vitamin D-dependent antimicrobial mech-
anism used by humanmacrophages in culture, we would
caution that there may well be additional mechanisms
for killing intracellular pathogens, including M. tuber-
culosis, by the macrophages of the human lung and
other tissues.
THE QUESTIONOF THE ROLE OF VITAMIN D
IN HUMAN TB AND LEPROSY
Vitamin D is produced in human skin exposed to UV
light. The circulating form is 25-hydroxyvitamin D, where
the hydroxyl group is added by the liver. The biologically
active form is 1,25-dihydroxyvitamin D, which we found
to be produced by the action of Cyp27B1 in activated
human macrophages (31). It had long been thought in
the pre-antibiotic era that exposure of TB patients to
sunshine and fresh air was helpful for recovery, and this
was the rationale for the sanatoriummovement in Europe
and the United States. Clearly exposure to UV light would
be expected to increase vitamin D levels, which might
have been helpful in recovery. There is a fascinating his-
torical study of cod liver oil, which is rich in vitamin D, in
TB patients at Brompton Hospital in London in 1848
(32). The results indicated that while cod liver oil cured
none of the patients, it arrested the disease in 18% of
patients and reduced mortality from 33 to 19%.
It is well known that African Americans have a
greater susceptibility to M. tuberculosis infection (33)
and that in the pre-antibiotic era they developed more
virulent forms of TB (34). Since melanin is known to
absorb UV light, this history suggested to us that dark-
skinned individuals might not have sufﬁcient levels of
vitamin D. In fact, a literature existed reporting that
African Americans had vitamin D levels at 10 to 20% of
what is considered normal. Consequently, we tested the
ability of human sera from African Americans and white
individuals to support the induction of cathelicidin in
TLR2-stimulated macrophages. The result was striking:
only 20% of the sera from African Americans had levels
of 25-hydroxyvitamin D, in the normal range and were
able to induce expression of cathelicidin mRNA. Addi-
tion of 25-hydroxyvitamin D, to the cultures enabled the
induction of cathelicidin mRNA to levels comparable to
those in the serum of white individuals and corrected the
defect (Fig. 5).
These results suggest the possibility that the increased
susceptibility of dark-skinned individuals from Africa
or Asia to TB might be related to insufﬁcient levels of
vitamin D. Consistent with these ﬁndings are time-series
epidemiological ﬁndings showing a parallel seasonal
variation in vitamin D levels and notiﬁcations of TB in
South Africa (35). There have been several in vivo
studies of vitamin D supplementation, with sometimes
conﬂicting results. A few contemporary clinical studies
have described a potential beneﬁt for vitamin D sup-
plementation as an adjuvant to chemotherapy, measur-
ing various endpoints including clinical and radiological
improvement (36–38), sputum conversion (37, 39), and
immune responses (38, 40, 41). However, these studies
were generally inconclusive due to a number of study
design confounders. While some studies showed short-
ening of the time to sputum clearance with chemother-
apy, others found no beneﬁcial effect. The studies were
subject to many confounding factors, including being
underpowered and being characterized by a low baseline
prevalence of vitamin D deﬁciency; seasonality and in-
creased levels of vitamin D in placebo controls; inade-
quate levels of supplementation due to dose and/or time;
lack of sputum cultures in some studies; and the absence
of agreed-upon, clearly deﬁned clinical endpoints. How-
ever, a recent study in which patients were treated with
high doses of vitamin D found clinical and radiological
improvement, including a reduction in the number of
cavities (38).
It is clearly challenging to ascertain a beneﬁcial effect
of vitamin D in patients who have active disease and are
of necessity receiving antimycobacterial drugs. Vitamin
D is not itself an antimicrobial drug, and it is asking a
great deal to see dramatic effects in patients with active
TB in which the tubercle bacillus has escaped protective
mechanisms such that there are enormous numbers of
bacilli in their tissues. If, as is believed, humans with
disease are infected with between 1 and 400 CFU of
6 ASMscience.org/MicrobiolSpectrum
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tubercle bacilli, it is possible that the greatest effect of
vitamin D would be in raising the threshold of innate
resistance to infection, and the effects of vitamin D
supplementation might be best found in healthy contacts
or patients with latent infection.
THE PARADOXICAL ROLE OF IFNs
From a variety of animal and human studies it has long
been known that type I IFNs (IFN-α and IFN-β) can
engender protection against many viral infections but
little protection against bacterial infections. As de-
scribed above, in both humans and mice, IFN-γ is es-
sential for protection against M. tuberculosis. Using
analysis of gene expression arrays on peripheral blood
of TB patients in Europe and in Africa, several labora-
tories have identiﬁed sets of genes that distinguish in-
dividuals with active TB disease from those with latent
infection (42, 43). The most striking characteristic of
the “signature” for active TB thus far is the increase in a
set of genes regulated by IFNs, in particular the type I
IFNs IFN-β and IFN-α (42, 44). The induction of the
type I IFN gene program was associated with the extent
of disease (42), and reversed completely by 2 months
of effective treatment (45). At the same time, studies
have shown that M. tuberculosis induces type I IFNs in
macrophages, requiring the ESX-1 secretion pathway
(46) for M. tuberculosis double-stranded DNA to gain
access to the cytoplasm, where it activates DNA sensors
including STING (47). In a mouse model, the hypervir-
ulent M. tuberculosis strain HN878 induced high levels
of type I IFN expression and low levels of IL-12p40 (48,
49), which augments Th1 responses. The spectrum of
leprosy offered a unique opportunity to investigate the
involvement of type I and type II IFNs in lesions of
the human disease. The results were striking: in tuber-
culoid leprosy, type I IFN-associated mRNAs were
hardly detectable, but there was evidence of type II IFN-
induced genes. In contrast, in lepromatous leprosy le-
sions, there was marked elevation of type I IFN-induced
genes, particularly IL-10 (50). In parallel, mRNAs for
Cyp27B1 and the VDR were elevated in tuberculoid
leprosy lesions.
When human macrophages were stimulated by IFN-γ
in vitro, there was elevation of mRNAs for the micro-
bicidal peptides cathelicidin and DEFB4. This stimula-
tion of the antimicrobial response was found to be
vitamin D dependent (29). In contrast, treatment of
peripheral blood adherent cells with IFN-β induced IL-
10. Simultaneous addition of IFN-γ and IFN-β resulted
in suppression of cathelicidin and DEFB4 mRNAs. This
inhibition of type II IFN activation was blocked by anti-
IL-10 antibody, indicating that the suppressive effect of
type I IFNs was mediated by IL-10 (50). When macro-
phages were activated by IFN-γ in serum sufﬁcient for
vitamin D, they were able to kill and reduce the viability
of M. leprae and M. tuberculosis. The process required
autophagy, and surprisingly, vitamin D was required for
autophagy as well (29). When type I IFN or IL-10 was
added, IFN-γ-induced killing was abrogated, and treat-
ment with anti-IL-10 restored the antimicrobial effect
(Fig. 6). These results demonstrate that type I and type II
IFNs have opposing effects on the microbicidal activity
of human macrophages and identify IL-10 as the medi-
ator of type I IFN suppression of antimicrobial activity
(Fig. 7).
FIGURE 6 Inhibition of the eﬀect of IFN-γ in stimulating induction of cathelicidin (Cath)
mRNA by IFN-β is mediated by IL-10. FC, fold change. *P ≤ 0.05. Source: reference 50.
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OBSERVATIONS ON MAJOR DIFFERENCES
BETWEEN HUMAN AND MURINE
ANTIMICROBIAL RESPONSES
One general theme that has arisen in these experiments
is that, despite many similarities, there are signiﬁcant
differences between human immune responses relating
to antimicrobial activity and those of the common ani-
mal models. Some examples include the following ob-
servations. (i) Most animal models of TB fail to exhibit
latency and human-like pathology. (ii) Mouse macro-
phages killM. tuberculosis predominantly by NO, while
human macrophages utilize microbicidal peptides, e.g.,
cathelicidin and DEFB4, and likely other mechanisms.
(iii) Human macrophage killing is vitamin D dependent,
while that by mouse macrophages is vitamin D inde-
pendent. (iv) While the human CAMP gene, the pre-
cursor of cathelicidin, has three vitamin D responsive
elements, its homolog in the mouse, a nocturnal animal,
has none. (v) DEFB4 has no mouse homolog; auto-
phagy in human M. tuberculosis-infected macrophages
is vitamin D dependent. (vi) CD1a, -b, and -c, which
present nonpeptide antigens to human T cells, have no
homologs in the mouse (which does have CD1d). (vii)
Human CD8 CTLs release the antimicrobial peptide
granulysin, which is lacking in mice. (viii) For IL-32, no
homolog has yet been found in mice.
FINDING A MARKER OF
PROTECTION AGAINST TB
One of the major problems in TB, particularly affecting
evaluation of new vaccines, is that we have no molecular
correlate of protection. Both the last major Mycobac-
terium bovis BCG trial in south India, with 360,000
subjects followed for 15 years (51), and a recent trial of a
new candidate vaccine, MVA85A, in South African in-
fants, regrettably showed no protection against M. tu-
berculosis infection or disease (52, 53). With about 40
vaccine candidates in preclinical trials, unless there is a
way to prioritize them on some rational scientiﬁc basis,
it is unlikely that hugely expensive large-scale efﬁcacy
trials will be undertaken. One exciting approach to de-
veloping such correlates is systems biology approaches,
speciﬁcally the study of gene expression proﬁles in pe-
ripheral blood of TB patients. Recently, several labora-
tories have identiﬁed a set of genes that distinguish
individuals with active TB disease from those with latent
infection (42, 43, 45, 54). The most striking character-
istic of the “signature” for active TB thus far is the in-
crease in the type I IFN-regulated genes (42, 44). Because
the type I IFN gene program was associated with extent
of disease (42), and response to treatment (45), the type I
IFN gene signature should be considered a “correlate of
risk or pathogenesis” for TB.
In contrast, in BCG-vaccinated children in South
Africa followed for 3 years for development of TB,
studies of production of cytokines by peripheral blood
cells, including IFN-γ, TNF-α, IL-12, and IL-17, were
unable to distinguish those who developed disease from
those who did not (55). We reasoned, however, that it
might be possible to gain insight into candidate molec-
ular “correlates of protection” by focusing on individ-
uals with evidence of M. tuberculosis infection who do
not progress to active disease. Consequently, we sought
to identify, in currently available data sets, those genes
that were more highly expressed in the blood of indi-
viduals with latent TB infection, as deﬁned by a positive
blood IFN-γ release assay, compared to individuals with
active TB and healthy controls. Using a sophisticated
bioinformatics approach known as weighted gene co-
expression network analysis, which searches for pair-
wise gene expression, an IL-15-induced host defense
module was identiﬁed in antimicrobial macrophages,
FIGURE 7 Common activation pathway for human macro-
phages stimulated through the innate receptor TLR2 or the
acquired immune activator IFN-γ. IFN-β suppresses that ac-
tivation through IL-10 by inhibiting induction of both CYP27B1
and the VDR. Source: reference 50.
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which contained among other genes IL-32 (56). When
these results were overlapped with the ﬁve existing data
sets of gene expression in peripheral blood of patients
with latent, active, or no TB, following informatics
analysis, there were eight genes expressed to a greater
extent in latent than in active patients, in healthy con-
trols, or in sarcoidosis and other diseases in which TB
was in the clinical differential diagnosis. Among those
genes was IL-32, which was induced in human mono-
cytes and macrophages by stimulation with IFN-γ (57)
or activation of NOD2 by muramyl dipeptide (58) or
of TLR4 by lipopolysaccharide (59). In the clinical
data sets, IL-32 was elevated in latent TB, depressed in
active disease, and returned to an intermediate level
following successful treatment of the patients. IL-32 was
found to be a central node in an IL-15-induced host de-
fense network of 48 genes, 35 of which were expressed
at baseline in the myeloid cell lineage in addition to
IL-32 (Fig. 8). The IL-15-induced IL-32 gene network
included vitamin D-related genes, e.g. cathelicidin, and
genes related to MHC class I activity and chemotaxis,
all of which could plausibly be related to antimicrobial
activity.
When humanmonocytes or macrophages were treated
with IL-32 in vitro, the vitamin D-dependent antimicro-
bial mechanism was activated to levels comparable to
activation with IFN-γ or IL-15 and M. tuberculosis was
killed by the IL-32-treated macrophages. This once again
was a vitamin D-dependent process.
Since IL-32 expression correlates with the latent state
of TB, which reﬂects a sufﬁcient immune response to
prevent the infection from progressing to active disease,
we believe IL-32 should be considered as one “correlate
of protection” against TB. Other biomarkers for pro-
tection are urgently needed to assess the likelihood of
success of any of the many vaccine candidates before
large-scale efﬁcacy trials are undertaken. We would sug-
gest that that may require a different scale of transla-
tional research on vaccines than has been considered
previously, with multiple small-scale vaccination studies
of human volunteers to develop a panel of molecular
biomarkers that might be useful markers of protection.
Such markers could markedly accelerate the develop-
ment and testing of effective vaccines against TB. Clearly
establishing any useful biomarkers for protection would
require independent veriﬁcation in other data sets and
ideally in a longitudinal vaccine trial that provided pro-
tection to a signiﬁcant number of recipients, where the
correlation with protection against disease could be
formally established. In the case of the vitamin D anti-
microbial mechanism described here, while we do not
know whether it is a necessary mechanism, we believe
the evidence we have developed over the past several
years clearly indicates that it is a sufﬁcient mechanism by
FIGURE 8 IL-15 defense response network links IL-32 to the vitamin D antimicrobial
pathway. The IL-15-induced host defense network reveals IL-32 as a hub gene, connected
to sets of genes involved in host defense, including the vitamin D antimicrobial pathway.
The color of each node depicts fold change (FC) induction by IL-15 at 24 h. Source:
reference 56.
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which human macrophages can kill intracellular bacte-
rial pathogens such as M. tuberculosis and M. leprae.
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